Emerging Markets

Latest Headlines

Latest Headlines

Vivo Capital doubles down to close $750M U.S.-China healthcare fund

Vivo Capital has closed an oversubscribed eighth fund at $750 million to invest in later-stage pharma and medical device companies in the U.S. and revenue-stage companies in greater China. That's precisely twice the size of its prior fund, which closed at $375 million in January 2012.

Malaysia's CCM Duopharma Biotech adds plants to compete better

A Malaysian drugmaker has bulked up its manufacturing capacity as it faces drugmakers from other countries building plants there to grab a piece of a market that is seeing the kind of growth hard to come by in other parts of the world.

Takeda transfers HPV vaccine rights as it continues globalization push

Takeda has been singing a globalization mantra when it comes to its vaccines unit, and that's already led it to dump one R&D program as it zeroes in on "higher impact" public health endeavors. Now, it's bowing out of another vaccine program--this time for HPV.

Glaxo plants a flag in Singapore with CEO Witty on hand

GlaxoSmithKline planted its flag in Singapore to build on a close relationship with the government of the wealthy city-state where CEO Andrew Witty worked and lived earlier in his career with the U.K. drugmaker.

Bharat's $1 rotavirus vaccine rolls out in India to challenge GSK, Merck

Back in 2011, Indian company Bharat Biotech pledged to offer its rotavirus prospect at a price that undercut even discounted vaccines from GlaxoSmithKline and Merck. Now, it's ready to make good on its promise.

China's Mindray jumps on acquisition rumor involving state-owned investment firm

The share price of China's Mindray Medical rose 16% last week on the New York Stock Exchange amid rumors that it will be taken over by private equity firms, including the country's state-owned investment company.

GSK sacks 100-plus China workers for misconduct in wake of bribery scandal

GlaxoSmithKline is breaking out the broom once again to clean up its act in China. It's dismissed more than 100 employees there for misconduct in part of what it calls a "zero tolerance" approach--but the fired workers aren't taking their dismissal lying down.

Aspen eyes more overseas buys after recent deals pay off

South Africa-based Aspen Pharmacare is looking for more overseas products and companies to snap up. CEO Stephen Saad tells Reuters that he's "looking the hardest" in Asia.

Jordan's MS Pharma gets $30M to expand manufacturing there

Western drugmakers finding their way into the Middle East and North Africa are being met by some domestic companies expanding operations in an effort to take on this competition. Among those is MS Pharma, which is now expanding manufacturing in Jordan with a loan from the European Bank for Reconstruction and Development.

Siemens Healthcare accused of faking contracts in China

Medical device companies have been jittery about being accused of corruption in China ever since the infamous crackdown on GlaxoSmithKline in 2013, which resulted in a $490 million fine for bribery.